EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document E2014G1106(01)
Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2013
Ravimid – EMP EFTA riikide poolt 2013. aasta esimesel poolaastal antud müügilubade nimekiri
Ravimid – EMP EFTA riikide poolt 2013. aasta esimesel poolaastal antud müügilubade nimekiri
ELT C 391, 6.11.2014, p. 3–14
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
6.11.2014 |
ET |
Euroopa Liidu Teataja |
C 391/3 |
Ravimid – EMP EFTA riikide poolt 2013. aasta esimesel poolaastal antud müügilubade nimekiri
2014/C 391/03
Kaupade vaba liikumise I allkomitee
Teadmiseks EMP ühiskomiteele
Vastavalt EMP ühiskomitee 28. mai 1999. aasta otsusele nr 74/1999 kutsutakse EMP ühiskomiteed 4. aprillil 2014 toimuval koosolekul arvesse võtma järgmisi ajavahemikus 1. jaanuarist30. juunini 2013 antud ravimite müügilubade nimekirju:
|
I lisa |
Uute müügilubade nimekiri |
|
II lisa |
Uuendatud müügilubade nimekiri |
|
III lisa |
Pikendatud müügilubade nimekiri |
|
IV lisa |
Äravõetud müügilubade nimekiri |
|
V lisa |
Peatatud müügilubade nimekiri |
I LISA
Uute müügilubade nimekiri
Ajavahemikus 1. jaanuarist30. juunini 2013 anti EMP EFTA riikides välja järgmised müügiload:
|
ELi number |
Toode |
Riik |
Loa andmise kuupäev |
|
EU/1/12/788/001-006 |
Seebri Breezhaler |
Liechtenstein |
30.4.2013 |
|
EU/1/12/789/001-006 |
Enurev Breezhaler |
Liechtenstein |
30.4.2013 |
|
EU/1/12/790/001-006 |
Tovanor Breezhaler |
Liechtenstein |
30.4.2013 |
|
EU/1/12/791/001 |
Glybera |
Liechtenstein |
30.4.2013 |
|
EU/1/12/795/001-010 |
Forxiga |
Liechtenstein |
30.4.2013 |
|
EU/1/12/797/001-002 |
Eylea |
Liechtenstein |
30.4.2013 |
|
EU/1/12/803/001-002 |
NexoBrid |
Liechtenstein |
30.4.2013 |
|
EU/1/12/803/001-002 |
NexoBrid |
Island |
14.1.2013 |
|
EU/1/12/803/001-002 |
NexoBrid |
Norra |
11.1.2013 |
|
EU/1/12/804/001-016 |
BindRen |
Liechtenstein |
30.4.2013 |
|
EU/1/12/804/001-016 |
BindRen |
Island |
8.2.2013 |
|
EU/1/12/804/001-016 |
BindRen |
Norra |
27.2.2013 |
|
EU/1/12/805 |
Amyvid |
Liechtenstein |
28.2.2013 |
|
EU/1/12/805/001-004 |
AMYViD |
Island |
6.2.2013 |
|
EU/1/12/805/001-004 |
AMYViD |
Norra |
4.2.2013 |
|
EU/1/12/806/001-005 |
Ryzodeg |
Liechtenstein |
28.2.2013 |
|
EU/1/12/806/001-005 |
Ryzodeg |
Island |
20.2.2013 |
|
EU/1/12/806/001-005 |
Ryzodeg |
Norra |
12.2.2013 |
|
EU/1/12/807/001-009 |
Tresiba |
Liechtenstein |
28.2.2013 |
|
EU/1/12/807/001-009 |
Tresiba |
Island |
20.2.2013 |
|
EU/1/12/807/001-009 |
Tresiba |
Norra |
12.2.2013 |
|
EU/1/12/808/001-040 |
Imatinib Teva |
Liechtenstein |
28.2.2013 |
|
EU/1/12/808/001-040 |
Imatinib Teva |
Island |
5.2.2013 |
|
EU/1/12/808/001-040 |
Imatinib Teva |
Norra |
22.1.2013 |
|
EU/1/12/809/001-014 |
Betmiga |
Liechtenstein |
28.2.2013 |
|
EU/1/12/809/001-014 |
Betmiga |
Island |
10.1.2013 |
|
EU/1/12/809/001-014 |
Betmiga |
Norra |
17.1.2013 |
|
EU/1/12/810 |
Krystexxa |
Liechtenstein |
30.4.2013 |
|
EU/1/12/810/001 |
Krystexxa |
Island |
14.1.2013 |
|
EU/1/12/810/001 |
Krystexxa |
Norra |
25.1.2013 |
|
EU/1/12/811/001-005 |
Lyxumia |
Island |
12.2.2013 |
|
EU/1/12/811/001-005 |
Lyxumia |
Norra |
12.2.2013 |
|
EU/1/12/812 |
Bexsero |
Liechtenstein |
28.2.2013 |
|
EU/1/12/812/001-004 |
Bexsero |
Island |
14.2.2013 |
|
EU/1/12/812/001-004 |
Bexsero |
Norra |
4.2.2013 |
|
EU/1/12/814 |
Zaltrap |
Liechtenstein |
28.2.2013 |
|
EU/1/12/814/001-003 |
Zaltrap |
Island |
12.2.2013 |
|
EU/1/12/814/001-003 |
Zaltrap |
Norra |
27.2.2013 |
|
EU/1/12/815/001-005 |
Selincro |
Liechtenstein |
30.4.2013 |
|
EU/1/12/815/001-005 |
Selincro |
Island |
19.3.2013 |
|
EU/1/12/815/001-005 |
Selincro |
Norra |
11.3.2013 |
|
EU/1/13/813/001 |
Perjeta |
Liechtenstein |
30.4.2013 |
|
EU/1/13/813/001 |
Perjeta |
Island |
20.3.2013 |
|
EU/1/13/813/001 |
Perjeta |
Norra |
9.4.2013 |
|
EU/1/13/817/001-041 |
Actelsar HCT |
Island |
21.3.2013 |
|
EU/1/13/817/001-041 |
Actelsar HCT |
Norra |
22.4.2013 |
|
EU/1/13/818/001-004 |
Bosulif |
Island |
15.4.2013 |
|
EU/1/13/818/001-004 |
Bosulif |
Norra |
30.4.2013 |
|
EU/1/13/819/001 |
JETREA |
Liechtenstein |
30.4.2013 |
|
EU/1/13/819/001 |
JETREA |
Island |
11.4.2013 |
|
EU/1/13/819/001 |
JETREA |
Norra |
22.3.2013 |
|
EU/1/13/820/001-026 |
Maruxa |
Liechtenstein |
30.6.2013 |
|
EU/1/13/820/001-026 |
Maruxa |
Norra |
24.5.2013 |
|
EU/1/13/821/001-030 |
Tolucombi |
Liechtenstein |
30.4.2013 |
|
EU/1/13/821/001-030 |
Tolucombi |
Island |
21.3.2013 |
|
EU/1/13/821/001-030 |
Tolucombi |
Norra |
22.3.2013 |
|
EU/1/13/823/001-002 |
Adasuve |
Norra |
12.3.2013 |
|
EU/1/13/823/001-002 |
Adasuve |
Liechtenstein |
30.4.2013 |
|
EU/1/13/823/001-002 |
Adasuve |
Island |
18.3.2013 |
|
EU/1/13/824 |
Nemdatine |
Liechtenstein |
30.4.2013 |
|
EU/1/13/824/001-020 |
Nemdatine |
Island |
21.5.2013 |
|
EU/1/13/824/001-020 |
Nemdatine |
Norra |
3.5.2013 |
|
EU/1/13/825 |
Imatinib Actavis |
Liechtenstein |
30.6.2013 |
|
EU/1/13/825/001-018 |
Imatinib Actavis |
Island |
16.5.2013 |
|
EU/1/13/825/001-018 |
Imatinib Actavis |
Norra |
20.6.2013 |
|
EU/1/13/826 |
Memantine LEK |
Liechtenstein |
30.4.2013 |
|
EU/1/13/826/001-011 |
Memantine LEK |
Island |
21.5.2013 |
|
EU/1/13/826/001-011 |
Memantine LEK |
Norra |
3.5.2013 |
|
EU/1/13/827 |
Memantine Mylan |
Liechtenstein |
30.4.2013 |
|
EU/1/13/827/001-036 |
Memantine Mylan |
Island |
21.5.2013 |
|
EU/1/13/827/001-036 |
Memantine Mylan |
Norra |
3.5.2013 |
|
EU/1/13/828 |
Hexacima |
Liechtenstein |
30.4.2013 |
|
EU/1/13/828/001-007 |
Hexacima |
Island |
17.5.2013 |
|
EU/1/13/828/001-007 |
Hexacima |
Norra |
15.5.2013 |
|
EU/1/13/829 |
Hexyon |
Liechtenstein |
30.4.2013 |
|
EU/1/13/829/001-007 |
Hexyon |
Island |
17.5.2013 |
|
EU/1/13/829/001-007 |
Hexyon |
Norra |
15.5.2013 |
|
EU/1/13/830/001-002 |
Stribild |
Island |
19.6.2013 |
|
EU/1/13/830/001-002 |
Stribild |
Norra |
24.5.2013 |
|
EU/1/13/835/001-018 |
Voriconazole Accord |
Island |
31.5.2013 |
|
EU/1/13/835/001-018 |
Voriconazole Accord |
Norra |
31.5.2013 |
|
EU/1/13/836 |
Memantine ratiopharm |
Liechtenstein |
30.6.2013 |
|
EU/1/13/836/001-023 |
Memantine ratiopharm |
Norra |
25.6.2013 |
|
EU/1/13/840/001-005 |
HyQvia |
Island |
27.5.2013 |
|
EU/1/13/840/001-005 |
HyQvia |
Norra |
3.6.2013 |
|
EU/2/12/142/001-006 |
Cardalis |
Norra |
20.6.2013 |
|
EU/2/12/144/001-004 |
Contacera |
Liechtenstein |
28.2.2013 |
|
EU/2/12/144/001-004 |
Contacera |
Island |
3.1.2013 |
|
EU/2/12/144/001-004 |
Contacera |
Norra |
17.1.2013 |
|
EU/2/12/145/001-003 |
Kexxtone |
Liechtenstein |
30.4.2013 |
|
EU/2/12/145/001-003 |
Kexxtone |
Island |
27.2.2013 |
|
EU/2/12/145/001-003 |
Kexxtone |
Norra |
8.3.2013 |
|
EU/2/12/146/001 |
Semintra |
Liechtenstein |
30.4.2013 |
|
EU/2/12/146/001 |
Semintra |
Island |
12.3.2013 |
|
EU/2/12/146/001 |
Semintra |
Norra |
5.4.2013 |
|
EU/2/12/147/001-004 |
Pexion |
Liechtenstein |
30.4.2013 |
|
EU/2/12/147/001-004 |
Pexion |
Island |
19.3.2013 |
|
EU/2/12/147/001-004 |
Pexion |
Norra |
8.3.2013 |
|
EU/2/13/148 |
Meloxidolor |
Liechtenstein |
30.6.2013 |
|
EU/2/13/148/001-007 |
Meloxidolor |
Island |
21.5.2013 |
|
EU/2/13/148/001-007 |
Meloxidolor |
Norra |
22.4.2013 |
|
EU/2/13/149 |
ECOPORC SHIGA |
Liechtenstein |
30.4.2013 |
|
EU/2/13/149/001-002 |
ECOPORC SHIGA |
Island |
15.5.2013 |
|
EU/2/13/149/001-002 |
ECOPORC SHIGA |
Norra |
13.5.2013 |
|
EU/2/13/150 |
Oncept IL-2 |
Liechtenstein |
30.6.2013 |
|
EU/2/13/151/001-003 |
Equilis West Nile |
Island |
27.6.2013 |
II LISA
Uuendatud müügilubade nimekiri
Ajavahemikus 1. jaanuarist30. juunini 2013 anti EMP EFTA riikides välja järgmised müügiload:
|
ELi number |
Toode |
Riik |
Loa andmise kuupäev |
|
EU/1/03/247 |
Forsteo |
Liechtenstein |
30.4.2013 |
|
EU/1/03/247/001–002 |
Forsteo |
Island |
19.2.2013 |
|
EU/1/03/247/001–002 |
Forsteo |
Norra |
6.3.2013 |
|
EU/1/07/423 |
Vectibix |
Liechtenstein |
30.4.2013 |
|
EU/1/07/423/001–003 |
Vectibix |
Island |
5.2.2013 |
|
EU/1/07/423/001–003 |
Vectibix |
Norra |
12.2.2013 |
|
EU/1/07/428/001 |
Abraxane |
Liechtenstein |
30.4.2013 |
|
EU/1/07/428/001 |
Abraxane |
Island |
5.2.2013 |
|
EU/1/07/428/001 |
Abraxane |
Norra |
11.2.2013 |
|
EU/1/07/430/001–002 |
Atripla |
Liechtenstein |
30.4.2013 |
|
EU/1/07/433/001 |
Nevanac |
Island |
9.1.2013 |
|
EU/1/07/434 |
Avamys |
Liechtenstein |
28.2.2013 |
|
EU/1/07/434/001–003 |
Avamys |
Island |
11.1.2013 |
|
EU/1/07/434/001–003 |
Avamys |
Norra |
14.1.2013 |
|
EU/1/07/435/001–018 |
Tesavel |
Liechtenstein |
30.4.2013 |
|
EU/1/07/438/001–006 |
Myfenax |
Liechtenstein |
30.4.2013 |
|
EU/1/07/439/001–006 |
Mycophenolate mofetil Teva |
Liechtenstein |
30.4.2013 |
|
EU/1/07/440 |
Tyverb |
Liechtenstein |
30.4.2013 |
|
EU/1/07/440/001–007 |
Tyverb |
Norra |
15.5.2013 |
|
EU/1/08/441 |
Effentora |
Liechtenstein |
30.4.2013 |
|
EU/1/08/441/001–010 |
Effentora |
Island |
20.3.2013 |
|
EU/1/08/441/001–010 |
Effentora |
Norra |
12.3.2013 |
|
EU/1/08/442/001–019 |
Pradaxa |
Norra |
26.2.2013 |
|
EU/1/08/442/001–019 |
Pradaxa |
Liechtenstein |
30.4.2013 |
|
EU/1/08/442/001–019 |
Pradaxa |
Island |
15.2.2013 |
|
EU/1/08/443/001 |
Thalidomide Celgene |
Island |
14.1.2013 |
|
EU/1/08/443/001 |
Thalidomide Celgene |
Norra |
16.1.2013 |
|
EU/1/08/446/001–006 |
Privigen |
Island |
22.3.2013 |
|
EU/1/08/446/001–006 |
Privigen |
Norra |
21.3.2013 |
|
EU/1/08/447/001–012 |
Adenuric |
Norra |
15.1.2013 |
|
EU/1/08/447/001–012 |
Adenuric |
Liechtenstein |
30.4.2013 |
|
EU/1/08/447/001–012 |
Adenuric |
Island |
14.1.2013 |
|
EU/1/08/448/001–002 |
Mycamine |
Liechtenstein |
30.4.2013 |
|
EU/1/08/448/001–002 |
Mycamine |
Island |
24.1.2013 |
|
EU/1/08/448/001–002 |
Mycamine |
Norra |
12.2.2013 |
|
EU/1/08/451 |
Volibris |
Liechtenstein |
30.4.2013 |
|
EU/1/08/451/001–004 |
Volibris |
Island |
5.2.2013 |
|
EU/1/08/451/001–004 |
Volibris |
Norra |
12.2.2013 |
|
EU/1/08/453 |
Prepandrix |
Liechtenstein |
30.4.2013 |
|
EU/1/08/453/002 |
Prepandrix |
Island |
6.2.2013 |
|
EU/1/08/453/002 |
Prepandrix |
Norra |
4.2.2013 |
|
EU/1/08/454/001–002, 005–007 |
Extavia |
Island |
9.1.2013 |
|
EU/1/08/454/001–002, 005–007 |
Extavia |
Liechtenstein |
30.4.2013 |
|
EU/1/08/454/001–002, 005–007 |
Extavia |
Norra |
10.1.2013 |
|
EU/1/08/455 |
Janumet |
Liechtenstein |
30.4.2013 |
|
EU/1/08/455/001–006 |
Janumet |
Norra |
10.4.2013 |
|
EU/1/08/455/001–016 |
Janumet |
Island |
25.3.2013 |
|
EU/1/08/456 |
Velmetia |
Liechtenstein |
30.4.2013 |
|
EU/1/08/456/001–016 |
Velmetia |
Island |
26.3.2013 |
|
EU/1/08/457 |
Efficib |
Liechtenstein |
30.4.2013 |
|
EU/1/08/457/001–016 |
Efficib |
Island |
26.3.2013 |
|
EU/1/08/461 |
Firazyr |
Liechtenstein |
30.4.2013 |
|
EU/1/08/461/001–002 |
Firazyr |
Island |
11.4.2013 |
|
EU/1/08/461/001–002 |
Firazyr |
Norra |
10.4.2013 |
|
EU/1/08/462 |
Ranexa |
Liechtenstein |
30.4.2013 |
|
EU/1/08/462/001–002 |
Ranexa |
Norra |
9.4.2013 |
|
EU/1/08/462/001–012 |
Ranexa |
Island |
20.3.2013 |
|
EU/1/08/463 |
Relistor |
Liechtenstein |
30.6.2013 |
|
EU/1/08/463/001–011 |
Relistor |
Island |
21.6.2013 |
|
EU/1/08/463/001–011 |
Relistor |
Norra |
26.6.2013 |
|
EU/1/08/465 |
Clopidogrel Zentiva |
Liechtenstein |
28.2.2013 |
|
EU/1/08/465/001–021 |
Clopidogrel Zentiva |
Island |
3.1.2013 |
|
EU/1/08/465/001–021 |
Clopidogrel Zentiva |
Norra |
5.2.2013 |
|
EU/1/08/467 |
Doribax |
Liechtenstein |
30.6.2013 |
|
EU/1/08/467/001–002 |
Doribax |
Island |
17.5.2013 |
|
EU/1/08/469 |
Oprymea |
Liechtenstein |
30.4.2013 |
|
EU/1/08/469/001–025 |
Oprymea |
Island |
14.5.2013 |
|
EU/1/08/469/001–025 |
Oprymea |
Norra |
24.5.2013 |
|
EU/1/08/472 |
Xarelto |
Liechtenstein |
30.6.2013 |
|
EU/1/08/472/001–033 |
Xarelto |
Norra |
13.6.2013 |
|
EU/1/08/472/001–033 |
Xarelto |
Island |
20.6.2013 |
|
EU/1/08/475 |
Olanzapine Mylan |
Liechtenstein |
30.6.2013 |
|
EU/1/08/475/001–060 |
Olanzapine Mylan |
Island |
20.6.2013 |
|
EU/1/08/475/001–060 |
Olanzapine Mylan |
Norra |
7.6.2013 |
|
EU/1/08/476 |
Adcirca |
Liechtenstein |
30.6.2013 |
|
EU/1/08/476/005–006 |
Adcirca |
Island |
31.5.2013 |
|
EU/1/08/476/005–006 |
Adcirca |
Norra |
4.6.2013 |
|
EU/1/10/625 |
Arzerra |
Liechtenstein |
30.4.2013 |
|
EU/1/10/625/001, 003 |
Arzerra |
Island |
15.3.2013 |
|
EU/1/10/625/001, 003 |
Arzerra |
Norra |
9.4.2013 |
|
EU/1/11/749 |
Caprelsa |
Liechtenstein |
30.4.2013 |
|
EU/1/11/749/001–002 |
Caprelsa |
Island |
12.3.2013 |
|
EU/1/11/749/001–002 |
Caprelsa |
Norra |
9.4.2013 |
|
EU/1/12/764 |
Pixuvri |
Liechtenstein |
30.4.2013 |
|
EU/1/12/764/001 |
Pixuvri |
Island |
12.4.2013 |
|
EU/1/12/764/001 |
Pixuvri |
Norra |
9.4.2013 |
|
EU/1/97/055/001–009 |
Viramune |
Liechtenstein |
30.4.2013 |
|
EU/1/97/055/001–009 |
Viramune |
Island |
14.1.2013 |
|
EU/1/97/055/001–009 |
Viramune |
Norra |
22.1.2013 |
|
EU/2/02/032/001–002 |
Vaxxitec HVT+IBD |
Norra |
11.6.2013 |
|
EU/2/03/037 |
ProteqFlu |
Liechtenstein |
30.4.2013 |
|
EU/2/03/037/005 |
ProteqFlu |
Island |
21.3.2013 |
|
EU/2/03/037/005 |
ProteqFlu |
Norra |
20.6.2013 |
|
EU/2/03/038 |
ProteqFlu-Te |
Liechtenstein |
30.4.2013 |
|
EU/2/03/038/005 |
ProteqFlu-Te |
Island |
21.3.2013 |
|
EU/2/03/038/005 |
ProteqFlu-Te |
Norra |
20.6.2013 |
|
EU/2/03/039 |
Advocate |
Liechtenstein |
28.2.2013 |
|
EU/2/03/039/001–054 |
Advocate |
Island |
19.2.2013 |
|
EU/2/03/039/001–054 |
Advocate |
Norra |
5.3.2013 |
|
EU/2/07/074/001–006 |
Prilactone |
Norra |
11.6.2013 |
|
EU/2/07/077/001–005 |
Meloxivet |
Norra |
5.4.2013 |
|
EU/2/07/078 |
Rheumocam |
Liechtenstein |
28.2.2013 |
|
EU/2/07/078/001–020 |
Rheumocam |
Island |
11.1.2013 |
|
EU/2/07/078/001–020 |
Rheumocam |
Norra |
21.1.2013 |
|
EU/2/07/079 |
Ingelvac CircoFLEX |
Liechtenstein |
30.4.2013 |
|
EU/2/07/079/001–008 |
Ingelvac CircoFLEX |
Island |
7.2.2013 |
|
EU/2/07/079/001–008 |
Ingelvac CircoFLEX |
Norra |
5.3.2013 |
|
EU/2/08/081/001–003 |
Posatex |
Island |
14.6.2013 |
|
EU/2/08/081/001–003 |
Posatex |
Norra |
11.6.2013 |
|
EU/2/08/083/001–005 |
Equioxx |
Island |
28.6.2013 |
|
EU/2/08/083/001–005 |
Equioxx |
Norra |
20.6.2013 |
III LISA
Pikendatud müügilubade nimekiri
Ajavahemikus 1. jaanuarist30. juunini 2013 pikendati EMP EFTA riikides järgmised müügiload:
|
ELi number |
Toode |
Riik |
Loa andmise kuupäev |
|
EU/1/01/200/003–009 |
Viread |
Norra |
11.1.2013 |
|
EU/1/02/221/017 |
Pegasys |
Island |
26.3.2013 |
|
EU/1/02/221/017 |
Pegasys |
Norra |
26.3.2013 |
|
EU/1/06/380/006–007 |
Prezista |
Liechtenstein |
28.2.2013 |
|
EU/1/06/380/007 |
Prezista |
Island |
6.2.2013 |
|
EU/1/06/380/007 |
Prezista |
Norra |
11.2.2013 |
|
EU/1/07/433/002 |
Nevanac |
Norra |
24.5.2013 |
|
EU/1/07/436/003–004 |
Isentress |
Island |
19.3.2013 |
|
EU/1/07/436/003–004 |
Isentress |
Norra |
25.2.2013 |
|
EU/1/08/468/003 |
Intelence |
Norra |
17.4.2013 |
|
EU/1/09/538/009–010 |
Afinitor |
Island |
5.2.2013 |
|
EU/1/09/538/009–010 |
Afinitor |
Norra |
16.1.2013 |
|
EU/1/09/576/041–042 |
Irbesartan Teva |
Liechtenstein |
28.2.2013 |
|
EU/1/11/690/003–004 |
Zoely |
Liechtenstein |
28.2.2013 |
|
EU/1/11/693/017–024 |
Rivastigmine Actavis |
Island |
17.5.2013 |
|
EU/1/11/693/017–024 |
Rivastigmine Actavis |
Norra |
25.6.2013 |
|
EU/1/12/750/002 |
Esmya |
Liechtenstein |
28.2.2013 |
|
EU/1/12/770/005 |
Docetaxel Kabi |
Liechtenstein |
28.2.2013 |
|
EU/1/98/066/027–030 |
Exelon |
Island |
7.2.2013 |
|
EU/1/98/066/027–030 |
Exelon |
Norra |
12.2.2013 |
|
EU/1/98/077/020–023 |
Viagra |
Island |
17.5.2013 |
|
EU/1/98/077/020–023 |
Viagra |
Norra |
15.5.2013 |
|
EU/100/146/033–037 |
Keppra |
Liechtenstein |
28.2.2013 |
|
EU/2/08/090/029–031 |
Loxicom |
Island |
21.3.2013 |
|
EU/2/08/090/029–031 |
Loxicom |
Norra |
6.3.2013 |
|
EU/2/10/115/016–019 |
Comfortis |
Island |
8.2.2013 |
|
EU/2/10/115/016–019 |
Comfortis |
Norra |
14.1.2013 |
|
EU/2/11/134/018–020 |
Inflacam |
Norra |
17.1.2013 |
IV LISA
Äravõetud müügilubade nimekiri
Ajavahemikus 1. jaanuarist30. juunini 2013 võeti EMP EFTA riikides ära järgmised müügiload:
|
ELi number |
Toode |
Riik |
Tagasivõtmise kuupäev |
|
EU/1/03/266 |
Bondenza |
Liechtenstein |
30.4.2013 |
|
EU/1/03/266/001–006 |
Bondenza |
Norra |
12.6.2013 |
|
EU/1/07/409 |
Riprazo |
Liechtenstein |
30.4.2013 |
|
EU/1/07/409/001–040 |
Riprazo |
Island |
27.5.2013 |
|
EU/1/07/409/001–040 |
Riprazo |
Norra |
14.3.2013 |
|
EU/1/08/458/001–014 |
Trevaclyn |
Island |
15.5.2013 |
|
EU/1/08/458/001–014 |
Trevaclyn |
Norra |
23.4.2013 |
|
EU/1/08/459/001–014 |
Tredaptive |
Island |
15.5.2013 |
|
EU/1/08/459/001–014 |
Tredaptive |
Norra |
23.4.2013 |
|
EU/1/08/460/001–014 |
Pelzont |
Island |
15.5.2013 |
|
EU/1/08/460/001–014 |
Pelzont |
Norra |
23.4.2013 |
|
EU/1/08/474/001–003 |
Alisade |
Island |
27.6.2013 |
|
EU/1/09/582/001 |
Rilonacept Regeneron |
Liechtenstein |
28.2.2013 |
|
EU/1/09/582/001 |
Rilonacept Regeneron |
Norra |
8.2.2013 |
|
EU/1/10/656/001–006 |
Possia |
Island |
15.4.2013 |
|
EU/1/10/656/001–006 |
Possia |
Norra |
12.6.2013 |
|
EU/1/11/683/001–080 |
Sprimeo HCT |
Norra |
21.3.2013 |
|
EU/1/12/754/001–021 |
Sepioglin |
Norra |
20.6.2013 |
|
EU/1/97/040/001–002 |
Teslascan |
Liechtenstein |
28.2.2013 |
|
EU/2/04/046 |
Nobivac Piro |
Liechtenstein |
30.6.2013 |
|
EU/2/04/046/001–003 |
Nobivac Piro |
Island |
3.6.2013 |
|
EU/2/04/046/001–003 |
Nobivac Piro |
Norra |
22.5.2013 |
V LISA
Peatatud müügilubade nimekiri
Ajavahemikus 1. jaanuarist30. juunini 2013 peatati EMP EFTA riikides järgmised müügiload:
|
ELi number |
Toode |
Riik |
Peatamise kuupäev |
|
EU/1/09/509/001–004 |
Ribavirin Teva |
Norra |
3.1.2013 |
|
EU/1/09/527/001–006 |
Ribavirin Teva Pharma BV |
Norra |
3.1.2013 |